CCMI
ACAD icon

Creative Capital Management Investments’s Acadia Pharmaceuticals ACAD Stock Holding History

Creative Capital Management Investments’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$759 Buy
+30
New +$660 ﹤0.01% 1174

Other funds holding ACAD

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
YCM
Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return
AB
Amalgamated Bank New York $14.5B AUM 44.3% 1-Year Est. Return

Creative Capital Management Investments's ACAD Position: Q2 2026 in Review

Creative Capital Management Investments opened a new position in Acadia Pharmaceuticals (ACAD) in Q2 2026: 30 shares worth $759. The stake represents ﹤0.01% of the portfolio and ranks #1174 among its holdings.

53 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Creative Capital Management Investments held 30 shares of Acadia Pharmaceuticals worth $759 as of Q2 2026.
  • Acadia Pharmaceuticals was a new Creative Capital Management Investments position in Q2 2026.
  • Acadia Pharmaceuticals made up ﹤0.01% of Creative Capital Management Investments's portfolio in Q2 2026, its #1174 holding.
  • 53 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Creative Capital Management Investments's 13F filing for Q2 2026, filed 24 Jul 2026.